InMed appoints John Bathery to board; director Baldasare to depart at AGM

InMed Pharmaceuticals Inc.

John Bathery appointed to Board effective Oct 14, 2025; Board expands to six members.
Bathery has 30+ years pharma experience, currently Head of Global BD at Takeda, led deals exceeding $60B.
Bryan Baldasare will not stand for re-election at 2025 AGM due to increasing professional obligations; no disagreements.
Bathery's expertise expected to support INM-901 (Alzheimer's) and INM-089 (AMD) programs toward clinical readiness and partnerships.
Bathery receives standard non-employee director compensation: $50,000 annual retainer, potential committee fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.